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Objectives 
To determine whether lipid-lowering therapy in 
patients with lower limb atherosclerosis is safe and 
effective in terms of alleviating symptoms, preventing 
deterioration ofunderlying disease and reducing mor- 
tality. 
Search Strategy 
Randomised controlled trials of lipid-lowering therapy 
in lower limb atherosclerosis were sought using the 
search strategy described by the Review Group, in- 
cluding hand-searching relevant medical journals and 
extensive MEDLINE searches. In addition, articles 
were identified from references in lipid-lowering 
papers, direct contact with principal investigators and 
pharmaceutical companies, and by EMBASE searches. 
Selection Criteria 
All trials of lipid-lowering therapy versus control were 
included. Studies in participants with claudication, 
critical imb ischaemia nd asymptomatic disease were 
eligible for inclusion, but not aortic disease or post- 
bypass surgery. Any therapeutic regimen aimed at 
reducing blood lipids was eligible, including diet or 
any agent specifically used to treat hyperlipidaemia. 
Trials eligible for inclusion were selected by GCL and 
checked by JFP. 
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Data Collection and Analysis 
Nine trials met the inclusion criteria, but two were 
excluded because of poor methodology. The included 
trials involved a total of just under 700 participants, 
and were conducted in seven different countries. Most 
commonly reported outcome measures were mortality, 
non-fatal events, angiographic change, the ABPI, walk- 
ing distance and side effects. The reviewers extracted 
the data independently, and odds ratios and weighted 
mean differences were estimated. 
Main Results 
Lipid-lowering therapy produced a marked but non- 
significant reduction in mortality (OR 0.21, 95% CI 
0.03-1.17), but little change in non-fatal events (OR 
1.21, 95% CI 0.80-1.83). In two trials there was a 
significant overall reduction in disease progression on 
angiogram (OR 0.47, 95% CI 0.29-0.76). The changes 
in ABPI and walking distance were inconsistent, al- 
though trials showed a general improvement in symp- 
toms which could not be combined in a statistical 
meta-analysis. 
Conclusions 
This review suggests that effective lipid-lowering ther- 
apy reduces mortality in patients with peripheral ar- 
terial disease and reduces progression of underlying 
atheroma, but these results must be interpreted with 
caution because they are based on a relatively small 
number of events. There is also some evidence that 
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treatment improves symptoms. However, variability 
between included trials means that care must be ex- 
ercised before generalising these conclusions to dif- 
ferent patient groups and treatment regimens. These 
results cannot determine whether one lipid-lowering 
regimen is better than another, but there is some 
evidence that probucol should be used with caution 
because of its adverse ffects on the lipoprotein profile. 
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